The Promise and the Reality

Commercial exosome products from donor cell lines have gained significant market attention with bold claims of trillions of particles per dose. However, CFT takes a fundamentally different approach – using your own biology to produce a complete, personalised biological preparation.

This comparison examines why the approach matters more than the particle count. A single exosome from a senescent, passage-expanded donor cell line is not equivalent to an exosome from a fresh, healthy patient cell. And a purified fraction of the secretome cannot deliver the complete regenerative symphony that the whole secretome provides.

Key Differences at a Glance

Autologous vs Donor-derived

Whole Secretome vs Purified Fraction

Personalised vs One-Size-Fits-All

No Immune Rejection vs Potential Cross-Reactivity

Quality vs Quantity

Head to Head

The Detailed Comparison

Factor	CFT	Allogeneic Exosomes
Source Material	Patient's own blood (150ml draw)	Donor cell lines (multiple passages)
Immune Compatibility	Perfect – recognised as self	Risk of immune rejection and cross-reactivity
Composition	Complete secretome: EVs, growth factors, cytokines, microRNAs	Purified exosome fraction only
Particle Quality	Fresh, passage-0 cells with intact biology	Passage 8-15+ cells with phenotypic drift
Personalisation	Tailored to individual biology	Generic, one-size-fits-all
Donor Pooling	Not applicable – single patient	5-20 donors pooled per batch
Cell Banking	Yes – bank once, treat many times	Not applicable
Regulatory Pathway	FDA 361 HCT/P classification	Varies; often requires 351 BLA pathway
Manufacturing	GMP-certified, single-patient processing	Large-scale industrial manufacturing
Cost Structure	Single blood draw, multiple doses	Ongoing donor sourcing and expansion

The Critical Factor

Quality Over Quantity

Particle count is a misleading metric when it ignores quality degradation. Passage-expanded cells undergo significant phenotypic drift. By passage 12, the exosomes produced are fundamentally different from those produced by fresh cells. The mRNA cargo changes, surface antigens shift, and biological potency diminishes.

Companies compensate by pooling donors – up to 20 individuals per batch. This further dilutes any claim to personalised medicine, introduces variability, and increases the risk of batch-to-batch inconsistency.

"Trillions of particles from senescent, passage-expanded donor cells do not equate to therapeutic potency."

The Immune Factor

The Immunological Advantage

Autologous material is recognised by the immune system as "self." This is a fundamental biological advantage that cannot be engineered away in donor products.

With CFT, there is zero risk of immune rejection, no cross-reactivity, and no foreign-body inflammatory responses. Your immune system actively cooperates with the therapy rather than working against it.

Allogeneic products, by definition, introduce foreign biological material. Even when processed to reduce immunogenicity, donor-derived exosomes remain detectably foreign at the molecular level. For some patients, this may trigger subclinical immune responses that reduce efficacy or cause adverse effects.

🛡️

The Verdict

Cell-Free Therapy delivers a complete, personalised biological preparation from your own cells. This eliminates immune rejection risk, avoids passage-induced degradation, and provides the full spectrum of regenerative signals rather than a purified fraction.

You get the whole secretome – not just exosomes. You get personalisation – not generic donor cocktails. And you get autologous safety – not allogeneic compromise.

See How CFT Compares to Other Approaches

Explore how Cell-Free Therapy stacks up against other regenerative therapies.

All Comparisons What is CFT?

CFT vs Allogeneic Exosomes